Filing Details

Accession Number:
0000921895-20-003153
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-12-01 19:45:50
Reporting Period:
2020-11-27
Accepted Time:
2020-12-01 19:45:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1599298 Summit Therapeutics Inc. SMMT Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1824493 Jonathan David Powell One Broadway
14Th Floor
Cambridge MA 02142
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-11-27 16,616 $1.92 16,616 No 4 M Direct
Common Stock Acquisiton 2020-11-27 12,953 $1.79 29,569 No 4 M Direct
Common Stock Disposition 2020-11-27 29,569 $4.39 0 No 4 S Direct
Common Stock Acquisiton 2020-11-30 13,713 $1.79 13,713 No 4 M Direct
Common Stock Disposition 2020-11-30 13,713 $4.44 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2020-11-27 16,616 $1.92 16,616 $1.92
Common Stock Stock Option (right to buy) Disposition 2020-11-27 12,953 $1.79 12,953 $1.79
Common Stock Stock Option (right to buy) Disposition 2020-11-30 13,713 $1.79 13,713 $1.79
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
417,639 2028-10-19 No 4 X Direct
404,686 2029-03-29 No 4 X Direct
390,973 2029-03-29 No 4 X Direct
Footnotes
  1. Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices.
  2. The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.30 to $4.66. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.
  3. The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.40 to $4.50. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.
  4. The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date.
  5. The option was granted on March 29, 2019. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date.